Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Transapical Technology Facilitates Cardiac Surgery

By HospiMedica International staff writers
Posted on 15 Oct 2013
A new surgical platform allows the delivery of aortic and mitral valves through the chest wall and the apex of the beating heart.

The Access, Stabilization, and Closure (ASC) system, in conjunction with minimally invasive surgical (MIS) techniques is used to deliver large-bore therapeutic devices into the beating heart of patients with structural heart disease, via the cardiac apex. More...
The system both seals and stabilizes the tissue of the access site during therapeutic device delivery, minimizing loss of blood from, or induction of air to the beating heart. On completion of the therapeutic treatment, it standardizes apical access and closure, leading to safer heart operations, decreased procedure time, and reduced technical challenges associated with transapical access and closure.

A multicenter clinical trial conducted in Germany of the ASC system demonstrated an excellent safety profile with 100% technical success, superior ease-of-use for surgeons, and reductions in both blood loss and operative time. Follow-up assessments of patients showed that the system provided robust closure, with no postoperative apical bleeding complications and no degradation of left ventricular function. The ASC system is a product of Apica Cardiovascular (Galway, Ireland), and has received the European community CE marking of approval.

“Clinically, the Apica ASC System is easy to use, standardizing apical access and closure. Its ‘sutureless’ access coil minimizes both rib spreading and patient pain, providing a dry access site with no peri-sheath bleeding,” said Prof. Thomas Walther, MD, of the Kerckhoff Klinik (Hamburg, Germany), who participated in the device’s clinical study. “Apical closure was reliable, rapid, and completely dry, demonstrating a reduction in operative times, blood loss, use of blood products and apical access site complications.”

“Apica has provided an excellent example of how a new medical device, which was initially conceived and developed overseas, could be brought to Ireland and developed here so that it can be made available for export to treat patients globally,” said James Greene, CEO of Apica Cardiovascular.

The transapical transcatheter aortic valve implantation (TAVI) approach is used for patients whose arteries are too small or too diseased for the transfemoral approach. The delivery system is designed for replacement valve implantation via the apex of the heart, which is reached through a small incision made between the ribs just below the left nipple. It is then expanded using a balloon to fit across the stenotic aortic valve, holding it open permanently.

Related Links:

Apica Cardiovascular



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.